Contact
searchSearch
HMP Global
Login

Glioma

Glioma
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Robert Fenstermaker, MD
Videos
SurVaxM Demonstrates Long-Term Survival Benefit in Younger Patients With Newly Diagnosed Glioblastoma
10/30/2026
Robert Fenstermaker, MD
Robert Fenstermaker, MD, discusses survival findings with the SurVaxM cancer vaccine in newly diagnosed patients with glioblastoma, highlighting improved long-term survival among younger patients, age-related differences in treatment benefit,...
Robert Fenstermaker, MD, discusses survival findings with the SurVaxM cancer vaccine in newly diagnosed patients with glioblastoma, highlighting improved long-term survival among younger patients, age-related differences in treatment benefit,...
Robert Fenstermaker, MD,...
10/30/2026
Oncology
Katherine Peters, MD, PhD
Videos
Safusidenib Demonstrates Durable Responses in IDH1-Mutant Glioma and Advances Into Expanded Clinical Development
10/06/2026
Katherine Peters, MD, PhD
Katherine Peters, MD, PhD, discusses results from the phase 2 J201 study evaluating safusidenib in patients with IDH1-mutat glioma, highlighting durable antitumor activity and the expanding clinical development of this targeted therapy before...
Katherine Peters, MD, PhD, discusses results from the phase 2 J201 study evaluating safusidenib in patients with IDH1-mutat glioma, highlighting durable antitumor activity and the expanding clinical development of this targeted therapy before...
Katherine Peters, MD, PhD,...
10/06/2026
Oncology
Brigitta Baumert, MD, PhD
Videos
Molecular Profiling Refines Prognosis and Treatment Selection in Low-Grade Glioma
07/28/2026
Brigitta Baumert, MD, PhD
Brigitta Baumert, MD, PhD, discusses long-term results from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with temozolomide in patients with clinically high-risk low-grade glioma, highlighting the prognostic value of...
Brigitta Baumert, MD, PhD, discusses long-term results from the phase 3 EORTC 22033-26033 trial comparing upfront radiotherapy with temozolomide in patients with clinically high-risk low-grade glioma, highlighting the prognostic value of...
Brigitta Baumert, MD, PhD,...
07/28/2026
Oncology
Jay Detsky, MD PhD
Videos
MRI-Guided Adaptive Radiotherapy Safely Reduces Treatment Margins in Glioblastoma
07/16/2026
Jay Detsky, MD, PhD
Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...
Jay Detsky, MD, PhD, discusses results from the phase 2 UNITED trial showing that MRI-guided adaptive radiotherapy safely reduced treatment margins while maintaining tumor control in patients with newly diagnosed glioblastoma, supporting...
Jay Detsky, MD, PhD, discusses...
07/16/2026
Oncology
Rimas Lukas, MD
Videos
IDO1 Inhibition Combined With Radiotherapy and Nivolumab Demonstrates Safety in Newly Diagnosed Glioblastoma
07/15/2026
Rimas Lukas, MD
Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...
Rimas Lukas, MD, discusses results from a phase 1 study showing that the IDO1 inhibitor BMS-986205 combined with radiotherapy and nivolumab demonstrated a manageable safety profile and established a recommended phase 2 dose in patients with...
Rimas Lukas, MD, discusses...
07/15/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Diego Prost, MD
Videos
18F-DOPA PET Improves Response Assessment in IDH-Mutant Glioma Treated With IDH Inhibitors
02/03/2026
Diego Prost, MD
Diego Prost, MD, discusses results from a retrospective study showing that 18F-DOPA PET detected metabolic responses not identified by MRI in patients with IDH-mutant glioma treated with IDH inhibitors, supporting metabolic imaging as a...
Diego Prost, MD, discusses results from a retrospective study showing that 18F-DOPA PET detected metabolic responses not identified by MRI in patients with IDH-mutant glioma treated with IDH inhibitors, supporting metabolic imaging as a...
Diego Prost, MD, discusses...
02/03/2026
Radiopharmaceutical Education Institute
Stephen Bagley, MD
Conference Coverage
Intracerebroventricular Delivery of CART-EGFR-IL13Rα2 Demonstrates Promise Among Patients With Recurrent Glioblastoma
08/05/2025
Stephen Bagley, MD
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses results from a phase 1 dose-exploration study which assessed intracerebroventricular delivery of CART-EGFR-IL13Rα2 among patients with recurrent glioblastoma.
Stephen Bagley, MD, discusses...
08/05/2025
Oncology
Michael Castro, MD
Videos
Effect of Proton Pump Inhibitor Use on Glioblastoma Survival Outcomes
06/13/2023
Michael Castro, MD, discusses the results of a retrospective study evaluating the effect proton pump inhibition use may have on survival outcomes of patients with glioblastoma.
Michael Castro, MD, discusses the results of a retrospective study evaluating the effect proton pump inhibition use may have on survival outcomes of patients with glioblastoma.
Michael Castro, MD, discusses...
06/13/2023
Oncology
Dorota Goplen, MD
Videos
Sequential Bortezomib Plus Temozolomide is Safe, Effective for Recurrent Glioblastoma
06/12/2023
Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 BORTEM-17 study evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and...
Dorota Goplen, MD, Haukeland University Hospital, Bergen, Norway, discusses results from a phase 1b/2 BORTEM-17 study evaluating the efficacy of sequential treatment with bortezomib and temozolomide for patients with glioblastoma and...
Dorota Goplen, MD, Haukeland...
06/12/2023
Oncology

Recent News

FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use